What to Do When Tricare Denies Zepbound: Step-by-Step Appeal

Introduction

Tricare denials for Zepbound® (tirzepatide) follow the same two-level appeal structure as other pharmacy denials, but the clinical arguments that win are specific to tirzepatide’s FDA indications. The December 2024 SURMOUNT-OSA approval added a separate indication that often unlocks coverage when weight-management arguments fail.

This is the step-by-step process: read the denial, gather documentation, file Level 1, request peer-to-peer if needed, escalate to Level 2, and pursue alternatives if both deny. It is grounded in current Tricare pharmacy policy and SURMOUNT-1 (Jastreboff et al. 2022 NEJM) and SURMOUNT-OSA trial data.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

STEP 1: Read the Denial Letter

The denial letter has three pieces of information that drive everything else: the denial code, the appeal deadline, and the policy citation. Find them first.

Quick Answer: Tricare covers Zepbound when PA criteria are met (BMI 30+ or 27+ with comorbidity)

Common denial codes include “PA criteria not met” (most common, most appealable), “step therapy required,” “non-formulary,” or “quantity limit exceeded.” Each requires a different appeal strategy.

The appeal deadline is 90 days from the denial date for Level 1 reconsideration. Mark it. Missing the deadline by one day ends the appeal regardless of merit.

STEP 2: Determine Whether You Qualify Under the OSA Indication

Zepbound was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This is a separate indication from chronic weight management, and Tricare may approve under OSA even when weight-management criteria fail.

The SURMOUNT-OSA trial showed tirzepatide reduced the apnea-hypopnea index by roughly 27-30 events per hour over 52 weeks. If you have a sleep study showing AHI of 15+ (moderate OSA), you qualify under the OSA indication.

If you do not have a recent sleep study, get one before filing the appeal. Tricare covers home sleep tests under standard medical benefits. A documented OSA diagnosis can change the entire framing of the appeal.

STEP 3: Gather Your Documentation

You need the denial letter, the original prescription, two years of medical records with diagnosis codes, prior weight-loss attempt documentation, and any comorbidity workup. Get all of it before drafting the appeal.

Medical records should document obesity (ICD-10 E66.01), OSA (G47.33) if applicable, type 2 diabetes (E11.9), hypertension (I10), and any cardiovascular history. The more documented comorbidities, the stronger the case.

Prior weight-loss attempts matter for the chronic weight management indication. Document phentermine trials, orlistat, dietitian visits, military weight programs (Navy Body Composition Assessment, Army Body Composition Program), and commercial programs with dates and outcomes.

STEP 4: Get a Letter of Medical Necessity

This is the most influential document in the file. It must come from a Tricare-credentialed prescriber and state the indication, diagnoses, and clinical rationale specifically.

The letter should name Zepbound and tirzepatide, state the FDA indication being claimed (chronic weight management OR moderate-to-severe OSA), list all comorbidities by ICD-10 code, cite SURMOUNT-1 (20.9% mean weight loss at 72 weeks) or SURMOUNT-OSA (27-30 AHI event reduction), and document prior treatment failures with dates and dosages.

Keep the letter to one page. Tricare reviewers favor clinical specificity over length.

STEP 5: File the Level 1 Reconsideration

Submit a written reconsideration request to Express Scripts within 90 days of the denial. The request can go by mail, fax, or through the Express Scripts member portal.

Include the appeal letter, medical necessity letter, supporting medical records, prior treatment documentation, and any sleep study or CV workup. Submit by certified mail or fax with confirmation, and keep copies of everything.

Express Scripts has 60 days to respond to the Level 1 reconsideration. Expedited review within 72 hours is available when the prescriber documents that delay would jeopardize health.

STEP 6: Request Peer-to-peer Review

Peer-to-peer review is a phone call between your prescriber and an Express Scripts clinical reviewer. It is optional and often resolves cases that fail on paper review.

Your prescriber requests the peer-to-peer through the Express Scripts portal or by phone. The call lasts 10-15 minutes. The reviewer either approves on the call or commits to a written decision within 5-7 business days.

Peer-to-peer is most effective when the case involves nuanced clinical detail. A patient with BMI 28, OSA, hypertension, and prior phentermine intolerance presents differently in conversation than on paper.

Key Takeaway: SURMOUNT-OSA indication (Dec 2024) unlocks coverage for moderate-severe sleep apnea

STEP 7: File the Level 2 Formal Appeal If Level 1 Denies

Level 2 appeals go to the Defense Health Agency. You have 90 days from the Level 1 denial to file. The appeal is decided based on the written record by a different reviewer than Level 1.

The Level 2 submission should include everything from Level 1 plus a written response addressing why the Level 1 reasoning was wrong. If Level 1 denied because of insufficient prior trial documentation, the Level 2 submission needs to fix that gap.

You can request a personal appearance for complex cases. Most appeals are resolved on documents within 60-90 days.

STEP 8: Consider Alternatives If Both Levels Deny

If both Level 1 and Level 2 deny, your remaining options are switching to a covered medication or cash-pay through a compounding provider.

Tricare-covered alternatives include phentermine, orlistat, and naltrexone-bupropion. None match Zepbound’s 20.9% efficacy from SURMOUNT-1, but they are accessible at standard copays.

Cash-pay compounded tirzepatide is the third path. TrimRx offers a free assessment quiz that screens eligibility and connects qualifying patients with licensed providers for a personalized treatment plan including compounded tirzepatide.

What Additional Considerations Apply to Active Duty Members?

Active duty members face readiness criteria that retirees and dependents do not. Zepbound use can affect deployment status, weight standards compliance, and physical readiness testing in some branches.

Active duty appeals usually need coordination with the military treatment facility pharmacy. PA approval may go through MTF channels rather than Express Scripts. Service-specific medical readiness regulations apply.

Talk to your military prescriber about deployment timeline and PRT cycle before starting Zepbound. The drug is generally compatible with continued service, but counseling on dosing schedule, side effects, and monitoring is important.

What Clinical Trial Citations Should Appear in the Appeal?

Three citations are essential depending on the indication being claimed. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) for chronic weight management, showing 20.9% mean weight loss at 72 weeks on the 15 mg dose. SURMOUNT-OSA for the OSA indication, showing AHI reduction of 27-30 events per hour over 52 weeks.

SURMOUNT-2 (Garvey et al. 2023 Lancet) shows tirzepatide efficacy in patients with type 2 diabetes and obesity. Citing this trial alongside SURMOUNT-1 strengthens appeals for patients with both conditions.

For Tricare appeals specifically, the policy manual references these trials by name. Citing the same studies the policy itself references shows clinical literacy and aligns the appeal language with how reviewers think about coverage decisions.

What Is the Role of the Military Treatment Facility Pharmacist?

For active duty members, the MTF pharmacist is often involved in PA approval and dispensing. The MTF pharmacy may submit the PA on behalf of the prescriber, particularly when the prescription is being filled at MTF.

Coordinate with the MTF pharmacy early. They know the local PA process, the typical timeline, and any service-specific considerations. Some MTF pharmacies have dedicated formulary management pharmacists who handle GLP-1 PAs specifically.

If the MTF cannot stock Zepbound (varies by facility size and budget), the prescription may need to fill at a network civilian pharmacy. This adds an additional approval step but is workable when documented properly.

Bottom line: Active duty members may need MTF approval in addition to Express Scripts

FAQ

How Long Does a Tricare Zepbound Appeal Take?

Level 1 reconsideration takes up to 60 days. Level 2 formal appeal takes another 60-90 days. Expedited review for urgent medical cases resolves within 72 hours.

Does Tricare Cover Zepbound for OSA?

Yes, when prior authorization criteria are met. You need a sleep study documenting AHI of 15+ (moderate OSA) and a BMI of 30+.

Can I Get Zepbound Through a Military Pharmacy?

Yes if approved. MTF pharmacies dispense Zepbound when PA is approved and the prescription routes through the military system. Active duty members are usually required to fill at MTF when stocked.

Does Tricare Cover Compounded Tirzepatide?

No. Tricare does not cover compounded medications. Compounded tirzepatide is cash-pay only.

What Is the Tricare Copay for Zepbound When Approved?

Tricare Select copay for non-formulary brand drugs runs $40-60 per 30-day supply. Tricare Prime copays are lower. Active duty pay nothing at MTF pharmacies.

Can I Switch From Zepbound to Mounjaro® to Get Tricare Coverage?

If you have type 2 diabetes, yes. Same active ingredient (tirzepatide). Mounjaro is on the Tricare formulary for diabetes management. Without a diabetes diagnosis, this does not work.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.